Calidi Biotherapeutics, Inc. (CLDI) Form 8-K — May 14, 2026
Calidi Biotherapeutics reported a Q1 2026 net loss of $4.4 million, a significant improvement from the $5.0 million loss in the same period last year, driven by a $1 million reduction in general and administrative expenses due to headcount and cost efficiencies. The company presented new preclinical data for its lead candidate CLD-401 at the AACR conference, highlighting profound immune changes in the tumor microenvironment and an expected IND filing by the end of 2026.
Key figures
- Cash Position
- 6631000
- Total assets
- 9591000
- Ga reduction yoy
- 1000000
- Total liabilities
- 4656000
- Ga expenses q1 2025
- 2637000
- Ga expenses q1 2026
- 1600000
- Rd expenses q1 2025
- 2425000
- Rd expenses q1 2026
- 2587000
- Weighted avg shares outstanding
- 10308000
Price after filing
Close on the filing date to close N calendar days later (from $0.19). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.